1 / 4

Viral Conjunctivitis Drugs Market Trends, Outlook and Opportunity Analysis 2018-2026

Viral conjunctivitis is an inflammation of the conjunctiva, which is a thin outermost layer of the sclera and inner layer of eyelid.<br>

rajbisen
Télécharger la présentation

Viral Conjunctivitis Drugs Market Trends, Outlook and Opportunity Analysis 2018-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Viral Conjunctivitis Drugs Market, by Drug Class, Viral Conjunctivitis Drugs Market, by Drug Class, Distribution Channel, and Geography - Global Industry Distribution Channel, and Geography - Global Industry Insights, Trends, Outlook and Opportunity Analysis 2018- Insights, Trends, Outlook and Opportunity Analysis 2018- 2026 2026 Viral conjunctivitis Viral conjunctivitis is an inflammation of the conjunctiva, which is a thin outermost layer of the sclera and inner layer of eyelid. Viral conjunctiva is caused due to infections from virus such as adenovirus, herpes simplex virus, varicella zoster virus, picornavirus, poxvirus, and human immunodeficiency virus. It is also called as Pinkeye disease. Viral conjunctivitis is characterized by the reddish eye, watery discharge from eye, and itching/irritation. Persistent conjunctivitis from virus may lead to corneal keratitis. Treatment for viral conjunctivitis may be symptomatic or virus specific. Treatment can include artificial tear drops to lower the dryness and irritation from infection, vasoconstrictors to reduce eye redness, decongestants to reduce the swelling, and antihistamines to reduce itching. Treatments usually are continued for one to two weeks, depending on the severity of the infection. Anti-viral therapy is utilized to treat infections from herpes simplex and varicella zoster virus. Download PDF Brochure Of This Research Report @ Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1281 https://www.coherentmarketinsights.com/insight/request-pdf/1281 Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Viral Conjunctivitis Drugs Market Research Objective and Assumption • Viral Conjunctivitis Drugs Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Viral Conjunctivitis Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Viral Conjunctivitis Drugs Market, By Regions • Viral Conjunctivitis Drugs Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Viral Conjunctivitis Drugs Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors.

  2. • Viral Conjunctivitis Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Viral Conjunctivitis Drugs Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion New drugs development in the U.S. to propel growth of the viral conjunctivitis market: New drugs development in the U.S. to propel growth of the viral conjunctivitis market: According to study published in the journal Ophthalmology in December 2017, approximately 80% of conjunctivitis cases in the U.S. are associated with viral conjunctivitis. According to study published in Review of Ophthalmology in January 2017, around 15 per 1000 population in the U.S. suffer from viral conjunctivitis. As per a study in Review of Optometry in 2016, an estimated 20,000 new cases, 48,000 cases of recurrences, and prevalence of 4,00,000 cases of herpes simplex keratitis were reported every year in U.S. Considering this facts, U.S. is expected to dominate the viral conjunctivitis drugs market. Also, increasing investment for development of new drugs to treat the viral conjunctivitis are further expected to propel the viral conjunctivitis drugs market growth. For instance, APD-209 is a drug candidate from Adenovir Pharma AB to treat epidemic keratoconjunctivitis from adenovirus, which has completed the phase 2 clinical studies in 2016. There is also increased awareness amongst patients about approaching the ophthalmologist to treat viral conjunctivitis. However, there is no direct anti-viral treatment available yet for conjunctivitis, which if available may open new opportunity in viral conjunctivitis drugs market. To treat viral conjunctivitis often it becomes difficult to clinically differentiate the viral conjunctivitis from the bacterial conjunctivitis which leads to miss diagnosis. Many physicians at primary care centers prescribe antibiotic to treat viral conjunctivitis due to miss diagnosis and this chain of events limits the expansion of viral conjunctivitis drugs market. According to 2017 study in Ophthalmology, an estimated 83% patients of acute conjunctivitis visited primary care centers instead of ophthalmologist, which leads to overlap of diagnosis and treatment of viral conjunctivitis in turn restraining market growth. Major Key Players: Major Key Players:

  3. Key players operating in the viral conjunctivitis drugs market include Bausch & Lomb, Allergan Key players operating in the viral conjunctivitis drugs market include Bausch & Lomb, Allergan plc, Shire plc, NicOx S.A, NovaBay Pharmaceuticals, Inc., NanoViricides, Inc., Novartis plc, Shire plc, NicOx S.A, NovaBay Pharmaceuticals, Inc., NanoViricides, Inc., Novartis International AG, Adenovir Pharma AB, Panoptes Pharma GES.M.B.H., Akorn Pharmaceuticals, International AG, Adenovir Pharma AB, Panoptes Pharma GES.M.B.H., Akorn Pharmaceuticals, and Quidel Corporation. Market players are investing in research to development of novel and Quidel Corporation. Market players are investing in research to development of novel therapies to treat viral conjunctivitis. therapies to treat viral conjunctivitis. Request For Customization of Research Report @ Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1281 https://www.coherentmarketinsights.com/insight/request-customization/1281 NiCox S.A. in March 2017, received the FDA approval for its ZERVIATE1 (cetirizine ophthalmic solution 0.24%) as New Drug Application (NDA), which is the first antihistaminic topical ocular formulation for the treatment of itching due to allergic conjunctivitis. Company is looking to commercialize the product in the U.S. through partnership. In 2015, Shire plc announced acquisition of Foresight Biotherapeutics for US$ 300 million. Foresight Biotherapeutics has experimental eye drop FST-100 in its pipeline, which is a combination of 0.6% povidone iodine and 0.1% dexamethasone to treat both viral and bacterial conjunctivitis. This acquisition would add growth to Shire plc’s ophthalmic portfolio. Viral Conjunctivitis Drugs Market Taxonomy: Viral Conjunctivitis Drugs Market Taxonomy: On the basis of drug class: • Artificial tears • Decongestants • Anti-histaminic • NSAIDS • Anti-Viral drugs On the basis of the distribution channel: • Hospital Pharmacy • Retail Pharmacy About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

  4. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com

More Related